Ann: Imugene Advances to Phase 2 in Gastric Cancer Trial, page-161

I think Platinum were selling in big chunks, 5m and 10m at a time. I guess they are finished now.

We have seen this before, they sell some probably because of cash calls or some internal reason.

But a year or so back the sp rocketed after they sold. Perhaps that will happen again.

Personally I think the phase 1b results will be decent, showing good early indications of efficacy. And I think that will be enough for big pharma to step in. The upside and massive market potential/disruption is too high for a big pharma to ignore (with figures like us$100b annual market in a few years for immunotherapies being forecasted).

And early deals can be worth a lot. Nektar got a us$1.85b deal from Bristol Myers, and Bristol only get 35% of any future profits.

https://www.forbes.com/sites/matthe...biotech-history-for-cancer-drug/#544cb10f6d29